Edward Henderson
Family Medicine · Collinsville, MSNPI 1346222890
Payments from drug & device makers
Across 348 payments — averaging $24.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$3K
- Novo Nordisk$869
- Amgen$729
- Johnson & Johnson$650
- AbbVie$538
- Boehringer Ingelheim$536
- plus $2K from 18 others
What the payments were for
- Food & beverage$8,583100%
- Education$200%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 72 | $2,844 |
| Novo Nordisk | 46 | $869 |
| Amgen | 26 | $729 |
| Johnson & Johnson | 16 | $650 |
| AbbVie(2 entities) | 27 | $538 |
| Boehringer Ingelheim | 13 | $536 |
| Lilly USA, LLC | 43 | $475 |
| Bayer | 14 | $387 |
| GSK | 17 | $245 |
| Pfizer | 19 | $240 |
| Amarin Pharma, Inc. | 11 | $172 |
| Abbott | 5 | $165 |
| Eisai Inc. | 9 | $143 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 7 | $108 |
| Mylan Specialty L.p. | 5 | $94 |
| Viiv Healthcare Company | 1 | $93 |
| Astellas Pharma US Inc | 3 | $61 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $60 |
| Novartis | 3 | $52 |
| Biohaven Pharmaceutical Holding Company Ltd. | 3 | $47 |
| Kowa Pharmaceuticals America, Inc. | 2 | $31 |
| Merck | 2 | $28 |
| E.r. Squibb & Sons, L.L.C. | 1 | $19 |
| Sanofi-aventis U.S. LLC | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$8,603 in reported general payments places this provider in the 90th percentile of 971 family medicine providers in Mississippi.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 180 | $206,408 |
| MounjaroTirzepatide | 166 | $198,127 |
| FarxigaDapagliflozin Propanediol | 186 | $150,788 |
| JardianceEmpagliflozin | 139 | $128,305 |
| EliquisApixaban | 144 | $125,491 |
| TrulicityDulaglutide | 88 | $93,294 |
| LinzessLinaclotide | 79 | $77,571 |
| RybelsusSemaglutide | 59 | $63,239 |
| JanuviaSitagliptin Phosphate | 73 | $60,283 |
| MyrbetriqMirabegron | 64 | $44,707 |
| Xigduo XrDapaglifloz Propaned/Metformin | 80 | $43,377 |
| XareltoRivaroxaban | 43 | $42,836 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 46 | $34,233 |
| KerendiaFinerenone | 35 | $27,315 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 33 | $26,620 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $475 | $291,421254 claims |
| Novo NordiskOzempic, Rybelsus | $869 | $269,648239 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Symbicort | $2,844 | $191,983255 claims |
| Boehringer IngelheimJardiance, Synjardy Xr, Tradjenta | $536 | $168,003191 claims |
| PfizerEliquis | $240 | $125,491144 claims |
| AbbVieLinzess, Ubrelvy | $538 | $89,76891 claims |
| MerckJanuvia, Janumet Xr | $28 | $68,51488 claims |
| Astellas Pharma US IncMyrbetriq | $61 | $44,70764 claims |
| Johnson & JohnsonXarelto | $650 | $42,83643 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $245 | $35,42363 claims |
| BayerKerendia | $387 | $27,31535 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $60 | $8,29315 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 971 family medicine providers in Mississippi.
Other family medicine in Collinsville
- Paul MatherneGulfport$14.4M
- Timothy QuinnRidgeland$8M
- Sean KerbyGulfport$6.6M
- Rambod RouhbakhshHattiesburg$6M
- Randall HulingOlive Branch$4.6M
- Demetri MarshallPort Gibson$3M
- Alexander OsowaJackson$2.2M
- Russell CarlisleWesson$1.6M
- Kristi TrimmRidgeland$1.2M
- Keith StokesLexington$660K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.